Gilead kept by Merrill at neutral

Gilead Sciences Inc. maintained its neutral rating by Merrill Lynch analyst Eric Ende. Gilead reported positive short-term data for GS-9137, its integrase inhibitor being developed for HIV in phase 1/2 studies. It appears that once-daily dosing is possible when boosted with ritonavir. If combination with Truvada is not convenient due to boosting, the market opportunity could be limited to $200 million to $400 MM compared to $1 billion or greater if boosting is not required. Shares of the Foster City, Calif., biopharmaceutical company were down $1.05, or 1.77%, at $58.33 on volume of 7,047,857 shares versus the three-month running average of 4,875,350 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.